



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: September 25, 2009

To: Primary Clinical Research Associates

From: Sara M. Braun
Research Protocol Specialist

Re: N0871, A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on June 10, 2009.

If you have any questions, please feel free to contact me.

Enclosure